L-TIL Plus Tislelizumab as Second Line Therapy for PD-1 Inhibitor Resistant Advanced NSCLC Patients
Latest Information Update: 27 May 2024
At a glance
- Drugs Docetaxel (Primary) ; Tislelizumab (Primary) ; Tumour infiltrating lymphocytes (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 21 May 2024 Planned End Date changed from 15 Sep 2024 to 15 Sep 2025.
- 21 May 2024 Planned primary completion date changed from 15 Sep 2023 to 15 Sep 2025.
- 29 May 2023 New trial record